Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. Vivos Therapeutics Inc. (VVOS) Message Board

Study Explores Link Between Obstructive Sleep Apne

Message Board Public Reply | Private Reply | Keep | Replies (0)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 51
(Total Views: 217)
Posted On: 11/18/2021 4:46:07 PM
Avatar
Posted By: NetworkNewsWire
Study Explores Link Between Obstructive Sleep Apnea and COVID-19

Obstructive sleep apnea (“OSA”) is a common sleep-related breathing disorder that causes individuals to repeatedly start and stop breathing while they sleep. There exist different types of sleep apnea, with the most common one being obstructive sleep apnea. Common symptoms of this particular type of sleep apnea include loud snoring, excessive daytime sleepiness, episodes of stopped breathing and awakening abruptly, which may be accompanied by choking or gasping.

A new study has found that patients with COVID-19 who suffer from obstructive sleep apnea have longer hospital stays and higher mortality rates when compared to patients with the coronavirus who don’t suffer from this sleep disorder. The study also found rates of obstructive sleep apnea were similar in patients with and without the coronavirus in the emergency department.

The study’s findings were reported in the “Sleep and Breathing” journal.

The objective of the researchers was to compare the prevalence of patients with obstructive sleep apnea who did or did not have the coronavirus infection who had been admitted to the same health center. In addition to this, the researchers also planned to assess the impact of this sleep disorder on clinical outcomes linked to the SARS-CoV-2 infection. The research was carried out at two sites in the Netherlands between March and May of last year.

The researchers enrolled more than 1,800 patients, roughly 700 of whom had been diagnosed with the coronavirus. The remaining number had tested negative for the infection, despite presenting with respiratory symptoms.

The researchers discovered that while the prevalence of the sleep disorder was similar in both groups, the mortality rate in those with the coronavirus was higher if they also suffered from obstructive sleep apnea. This was in comparison to the mortality rate of those without the sleep disorder.

In their report, the researchers note that the heightened risk of death among those with both the sleep disorder and the coronavirus was independent of obstructive lung ailments, diabetes, cardiovascular illnesses, male gender, age and body mass index. The percentage of those who had been admitted to the ICU was also higher in patients with the sleep disorder and the coronavirus, as compared to the other group.

Additionally, the researchers stated in their report that the study’s findings show that obstructive sleep apnea should be incorporated into risk factor analyses for the coronavirus. They then noted that physicians needed to be aware of the relationship between the outcomes of the coronavirus and obstructive sleep apnea, adding that more research needed to be conducted on the mechanism underlying this relationship.

Given that OSA has been found to worsen the way in which COVID-19 affects patients, it is important for those diagnosed with obstructive sleep apnea to seek treatment using any of the available options on the market, such as those offered by Vivos Therapeutics Inc. (NASDAQ: VVOS) so that any secondary illness they develop is easier to manage.

NOTE TO INVESTORS: The latest news and updates relating to Vivos Therapeutics Inc. (NASDAQ: VVOS) are available in the company’s newsroom at http://ibn.fm/VVOS

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer




(0)
(0)




Vivos Therapeutics Inc. (VVOS) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us